Day Traders Diary
The stock market ended a volatile week on a modestly lower note as investors eyed a downturn in the heavily-weighted health care (-1.1%) and technology (-0.9%) sectors. As a result, the tech-heavy Nasdaq (-0.9%) finished behind the S&P 500 (-0.3%). For the week, the two indices lost a respective 1.9% and 1.2%.
Equity indices began on a choppy note as investors weighed a rebound in global bourses against recent remarks from St. Louis Fed President and FOMC voter James Bullard. The Fed President announced earlier this morning that he has re-thought his global economic outlook, projecting that one rate hike may be appropriate through 2018. This accentuates diminished rate-hike expectations from the FOMC's June Policy Statement, which showed a lowered projection for the fed funds rate in 2017 (to 1.6% from 1.9%) and 2018 (to 2.4% from 3.0%).
On the other hand, global bourses saw a reprieve from their recent sell-off as participants weighed developments in the ongoing Brexit campaign. Both camps agreed to suspend their respective campaigns for another day following yesterday's fatal attack on MP Jo Cox. As a result, safe havens swooned while risk assets rebounded.
The benchmark index fell through the morning, eventually finding support near the 2062 area. Equities advanced steadily through the afternoon, but the S&P 500 (-0.3%) sputtered out short of its flat line and its 50-day simple moving average (2078.02). Five sectors ended in the red with health care (-1.1%), technology (-0.9%), and consumer staples (-0.5%) rounding out the board. Commodity-sensitive energy (+0.8%) led countercyclical telecom services (+0.6%) in front of the pack.
The health care space (-1.1%) extended its weekly decline to 2.1% as Dow component Merck (MRK 55.89, -1.61) and the biotechnology group weighed. Merck lost 2.8% today after rallying 2.5% on Thursday. In the biotechnology sub-group, Regeneron Pharmaceuticals (REGN 354.21, -12.31) and Vertex Pharmaceuticals (VRTX 86.73, -3.68) lost 3.4% and 4.1%, respectively. Regeneron was pressured after Canaccord Genuity made bullish comments regarding a competitor's medication. Meanwhile, Vertex fell after the U.K.'s National Institute for Health and Care Excellence failed to recommend the company's cystic fibrosis drug.
In the technology sector (-0.9%), Apple (AAPL 95.33, -2.22) underperformed after reports indicated that regulators in China ordered the company to halt sales of its iPhone 6 due to a patent dispute. The company said its products remain available for sale and that an appeal will be filed. Elsewhere, Alphabet (GOOG 691.72, -18.64) fell to a multi-month low (688.45) after Citigroup issued cautious commentary regarding the company's second-quarter results.
The Dow Jones Transportation Average (+0.6%) trimmed its weekly loss to 2.3% as rail names outperformed. Additionally, the U.S. Global Jets ETF (JETS 21.54, +0.07) rebounded 0.3%, trimming its weekly loss to 9.0%.
The commodity-sensitive energy sector (+0.8%) trimmed its loss to 0.1% as WTI crude rebounded. The energy component finished its day higher by 4.0% ($48.02/bb; +$1.84). For the week, the commodity lost 2.1%.
The U.S. Dollar Index (94.17, -0.40) ended near its low as the euro and the pound gained against the dollar. The euro finished higher by 0.5% against the buck (1.1277) while sterling climbed 1.1% against the dollar (1.4354).
The Treasury complex ended near its low as the yield on the 10-yr note rose three basis points to 1.61%.
Today's volume was above the recent average with more than two billion shares changing hands on the NYSE floor. The increased total was due to quadruple witching, which marks the expiration of index options, index futures, stock options, and single-stock futures.
Economic data was limited to the Housing Starts and Building Permits Report for May:
Housing starts decreased 0.3% to a seasonally adjusted annual rate of 1.164 million (Briefing.com consensus 1.150 mln) in May.
This follows a revised April estimate of 1.167 million (from 1.172 mln)
Building permits increased 0.7% to 1.138 million (Briefing.com consensus 1.150 mln) from the revised April rate of 1.130 million (from 1.116 mln).
Altogether there wasn't anything overwhelming about the monthly report.
Arguably, it was a bit disappointing considering that there was minimal growth (+0.3%) in single-family starts to 764,000 and that permits for single-family units -- a leading indicator -- were down 2.0%, led by declines in the Northeast (-8.9%), the West (-5.1%), and the Midwest (-3.5%).
The South was the only region to see an increase in permits for single-family units (+0.8%).
A 33.3% decline in starts in the Northeast, all of which was owed to a decline in multi-unit starts, was the big drag on total housing starts. A 14.7% decline in single-family starts in the Midwest also weighed.
Notwithstanding the relatively soft monthly figures, total housing starts were up 9.5% year-over-year. Building permits, however, were down 10.1% on the same basis given large drops in permits for multi-unit dwellings.
On a good note for second quarter GDP forecasts, the number of units under construction at the end of the period jumped to 1.019 million from 1.001 million in April.
The second quarter average for this metric is 2.5% above the first quarter average.
There is no economic data of note scheduled for release on Monday.
Nasdaq Composite -4.1% YTD
Russell 2000 +0.8% YTD
S&P 500 +1.3% YTD
Dow Jones +1.4% YTDAll comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.